Lv21
150 积分 2025-03-26 加入
Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity
35分钟前
待确认
Sirtuins in Alzheimer’s disease: mechanistic insights and therapeutic opportunities
5小时前
已完结
Discovery of BRD9 Molecular Glue Degraders That Spare Cardiomyocytes
1个月前
已完结
LRRK2 in Parkinson disease: challenges of clinical trials
1个月前
已完结
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
1个月前
已完结
AI-driven protein design
2个月前
已完结
Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)
2个月前
已完结
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
2个月前
已完结
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
2个月前
已完结
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
2个月前
已完结
皖公网安备34019202002308
